Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252096 · ClinicalTrials.gov registry record · NA
Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections
A NA study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- NA
- Development phase
- 3,900
- Enrollment target
NCT00252096 is a NA study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 3,900 participants.
The verdict
NCT00252096, a NA study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,900 participants
- Enrollment target
Study Summary
Investigators at the University of Alabama in Birmingham in collaboration with investigators from the Centers for Disease Control in Atlanta are evaluating the performance of three commercial nucleic acid amplification tests for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in pharyngeal and rectal swab specimens. Cultures for C. trachomatis and N. gonorrhoeae are performed as additional reference tests. Study subjects are men and women attending sexually transmitted disease (STD) and HIV care clinics in Birmingham, Alabama, who report sexual behaviors that place them at risk for pharyngeal or rectal sexually transmitted infections.
Interventions
- DEVICE Nucleic acid amplification test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,900 participants |
| Start Date | 2003-06 |
| Est. Completion | 2010-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252096
The ClinicalTrials.gov registry entry for NCT00252096 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nucleic acid amplification test is the first listed.
NCT00252096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252096 about?
NCT00252096 is a clinical study titled "Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections". Investigators at the University of Alabama in Birmingham in collaboration with investigators from the Centers for Disease Control in Atlanta are evaluating the performance of three commercial nucleic acid amplification tests for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in pha...
What is the current status of trial NCT00252096?
This trial is currently completed. It is a NA study. The enrollment target is 3,900 participants. The study started on 2003-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00252096?
The interventions under investigation include: Nucleic acid amplification test (DEVICE).
Who is sponsoring clinical trial NCT00252096?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.